NextPharma Technologies Awarded Frost & Sullivan 2006 Growth Strategy Leadership Award
London, UK – 24 March 2006
NextPharma Technologies - a leading provider of product development and manufacturing outsourcing services to the rapidly growing biotech and pharmaceutical industry, is delighted to report that it has been awarded the Frost & Sullivan 2006 Growth Strategy Leadership Award for the European Pharmaceutical Contract Manufacturing Market.
Each year, Frost & Sullivan present this Award to the company that has demonstrated an exceptional growth strategy within their industry. More specifically, the Award is given to the company that has bolstered their position in the market and whose strategy will have a lasting impact on the market.
“NextPharma has diversified its business to a major extent by catering to a wide range of clients within the healthcare industry rather than focusing on a select group,” said Frost & Sullivan Research Analyst Barath Shakar. “The 'end-to-end' service business model offered by NextPharma ensures that reducing the time to market while also reducing cost of the product enhances the client's profitability. NextPharma, through its Growth Strategy Leadership, has laid a path to become one of the leaders in the global pharmaceuticals contract manufacturing market.”
“It is a great honour to receive this Award which is a direct result of the collective efforts of the entire NextPharma team. Our strategy of focusing on solving our customers’ problems across the supply chain, from product development through manufacturing to distribution, is ensuring that we are becoming our customers’ outsourcing partner of choice” commented Bill Wedlake, CEO, NextPharma Technologies. “The “one-stop” service that we provide decreases the number of supply chain participants and requires fewer resources to manage, which in turn reduces costs to our client’s.”
About NextPharma
NextPharma Technologies is a leading independent supplier in the fast growing pharmaceutical and biotech product development, clinical trials supplies, manufacturing and logistics outsourcing sector. It has five product development, eight manufacturing and five logistics facilities based in Austria, Belgium, France, Germany and Switzerland employing over 1,200 people and has a customer base which includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies. NextPharma’s principle shareholder is Credit Suisse First Boston Private Equity.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.